Abstract

Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.

Original languageEnglish (US)
JournalNature Reviews Drug Discovery
Volume4
Issue number5 SUPPL.
DOIs
StatePublished - May 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Pharmaceutical Preparations
Epidermal Growth Factor Receptor
Drug Therapy
Survival
Erlotinib Hydrochloride
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Erlotinib hydrochloride. / Dowell, Jonathan; Minna, John D.; Kirkpatrick, Peter.

In: Nature Reviews Drug Discovery, Vol. 4, No. 5 SUPPL., 05.2005.

Research output: Contribution to journalArticle

Dowell, Jonathan ; Minna, John D. ; Kirkpatrick, Peter. / Erlotinib hydrochloride. In: Nature Reviews Drug Discovery. 2005 ; Vol. 4, No. 5 SUPPL.
@article{fbf0dfa034b54fd48d35f114ec89b621,
title = "Erlotinib hydrochloride",
abstract = "Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.",
author = "Jonathan Dowell and Minna, {John D.} and Peter Kirkpatrick",
year = "2005",
month = "5",
doi = "10.1038/nrd1730",
language = "English (US)",
volume = "4",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Erlotinib hydrochloride

AU - Dowell, Jonathan

AU - Minna, John D.

AU - Kirkpatrick, Peter

PY - 2005/5

Y1 - 2005/5

N2 - Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.

AB - Erlotinib hydrochloride (Tarceva; OSI Pharmaceuticals/Genentech/Roche), a member of a class of targeted anticancer drugs that inhibit the activity of the epidermal growth factor receptor, was approved by the US FDA in November 2004 for the treatment of advanced non-small-cell lung cancer after failure of at least one prior chemotherapy regimen. It is the first such drug to demonstrate an increase in survival in Phase III trials in patients with advanced non-small-cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=18744400294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744400294&partnerID=8YFLogxK

U2 - 10.1038/nrd1730

DO - 10.1038/nrd1730

M3 - Article

C2 - 15962526

AN - SCOPUS:18744400294

VL - 4

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 5 SUPPL.

ER -